Drugs and medicine – Scuba Dive Talks http://scubadivetalks.com/ Tue, 21 Sep 2021 20:26:01 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://scubadivetalks.com/wp-content/uploads/2021/07/scuba.png Drugs and medicine – Scuba Dive Talks http://scubadivetalks.com/ 32 32 Chiropractic For Migraine: Does It Work? https://scubadivetalks.com/chiropractic-for-migraine-does-it-work/ https://scubadivetalks.com/chiropractic-for-migraine-does-it-work/#respond Tue, 21 Sep 2021 19:55:19 +0000 https://scubadivetalks.com/chiropractic-for-migraine-does-it-work/ The evidence for the effectiveness of chiropractic for migraines is limited. However, some studies suggest that it may be as effective as other preventative drugs that doctors prescribe for the condition. According to the oldest 2011 research, there may be some benefits to having chiropractic treatment to prevent migraines. Chiropractic is an alternative and complementary […]]]>

The evidence for the effectiveness of chiropractic for migraines is limited. However, some studies suggest that it may be as effective as other preventative drugs that doctors prescribe for the condition.

According to the oldest 2011 research, there may be some benefits to having chiropractic treatment to prevent migraines. Chiropractic is an alternative and complementary medicine that treats conditions affecting bones, muscles, nerves, ligaments, and tendons.

People can see a chiropractor for migraine because they often have associated symptoms, such as neck pain and stiffness, which chiropractors commonly treat. According to American Chiropractic Association (ACA), treatment may involve spinal manipulations and soft tissue therapies, as well as lifestyle counseling on nutrition, exercise, and posture.

The Migraine Research Foundation report that 39 million people in the United States suffer from migraines. It is more common in people between the ages of 18 and 44.

Keep reading to learn more about using chiropractic for migraine, how it works, how safe it is, and how effective it is during pregnancy.

Migraine has no cure, and many medications that doctors prescribe for migraine have serious side effects. For this reason, individuals often opt for alternative or complementary therapies, such as chiropractic.

Although the symptoms of migraines vary, more than 75% of people with the disease, associated neck pain. Many of them also report muscle tension, neck stiffness, and jaw function issues.

Doctors typically prescribe nonsteroidal anti-inflammatory drugs, muscle relaxants, and physical therapy to treat these associated symptoms. However, these treatments do not completely solve the problems underlying the symptoms. The expertise of a chiropractor includes the treatment of these symptoms and often relieves the underlying problems.

The evidence for the safety and effectiveness of chiropractic treatment for migraines is limited but encouraging. One older 2011 review evaluated clinical trials on the effects of chiropractic spinal manipulation, massage therapy, and physiotherapy for migraine headaches.

The results suggest that each of the therapies may be as effective as conventional preventative drugs, such as propranolol (Inderal) and topiramate (Topamax). However, the review found gaps in clinical trials, which led the authors to request further studies, following strict clinical guidelines.

Despite limited research on chiropractic for migraine headaches, treating the condition accounts for a substantial percentage of practitioner workload.

A 2017 survey surveyed 1,869 chiropractors to determine the prevalence of migraine treatment and management. The results showed that 53% had a high workload among people with migraine headaches.

To treat migraines, chiropractors perform spinal adjustments or manipulations to reduce stress and improve spinal function. The treatment too understand soft tissue therapies, which may involve:

  • massage, which includes kneading the joints and muscles
  • myofascial release massage targeting membranes that connect and support muscles
  • trigger point therapies that target tight areas in muscles

According to TO THAT, chiropractic for migraines also offers lifestyle management suggestions, such as:

  • make dietary changes and take B-complex vitamins
  • avoid strenuous exercise and encourage walking and low-impact aerobics
  • advice on posture, such as sitting correctly at work

Additionally, chiropractic may include other lifestyle recommendations that can help prevent migraines. Examples include advice on clenching teeth, which can stress the jaw joint and trigger headaches, and encourage people to drink plenty of water each day to prevent dehydration, which is another trigger for it. headache.

The goal of a chiropractor when treating migraines is to reduce pain and maximize neuromusculoskeletal health. Experts aren’t sure exactly how the treatment helps, but believe it’s likely due to its multi-faceted approach. For example, reducing muscle tension can decrease overall musculoskeletal pain.

Some experts are concerned that the side effects of preventative drugs could affect the health of a pregnant person and the developing fetus.

As such, a pregnant person might consider taking additional therapy, such as chiropractic.

There is little research on the use of chiropractic for migraine during pregnancy. However, a former case study 2009 suggests that it can be safe and effective.

The study involved a 24-year-old woman who was pregnant and had suffered from chronic migraines for 12 years. His previous unsuccessful treatments included massage therapy, physiotherapy, and some other type of complementary therapy. She also took nonsteroidal anti-inflammatory drugs with codeine, but this only provided minor temporary relief.

After chiropractic spinal manipulation treatment and complementary therapies, her symptoms improved and she became independent of medication. More research is needed, but the case study suggests that chiropractic may be safe and effective for treating migraines during pregnancy.

People often see a chiropractor for migraine treatment because they get relief from the disease but don’t experience the side effects that they can get from medications.

Studies are limited, but earlier research indicates that chiropractic can help treat migraines.

Even fewer studies have examined the use of chiropractic treatment for migraines during pregnancy, but a case study suggests that it is effective and safe.


Source link

]]>
https://scubadivetalks.com/chiropractic-for-migraine-does-it-work/feed/ 0
Lincoln Pharma allocates approximately Rs 30 cr for expansion of cephalosporin product portfolio, Health News, ET HealthWorld https://scubadivetalks.com/lincoln-pharma-allocates-approximately-rs-30-cr-for-expansion-of-cephalosporin-product-portfolio-health-news-et-healthworld/ https://scubadivetalks.com/lincoln-pharma-allocates-approximately-rs-30-cr-for-expansion-of-cephalosporin-product-portfolio-health-news-et-healthworld/#respond Tue, 21 Sep 2021 11:11:00 +0000 https://scubadivetalks.com/lincoln-pharma-allocates-approximately-rs-30-cr-for-expansion-of-cephalosporin-product-portfolio-health-news-et-healthworld/ New Delhi: Pharmaceutical company Lincoln Pharmaceuticals said on Tuesday it had earmarked an investment of around Rs 30 crore to expand its portfolio of cephalosporin products and plan to launch them soon in India. The company has also acquired a facility in Mehsana for this and expects commercial operations at the plant to begin from […]]]>
New Delhi: Pharmaceutical company Lincoln Pharmaceuticals said on Tuesday it had earmarked an investment of around Rs 30 crore to expand its portfolio of cephalosporin products and plan to launch them soon in India. The company has also acquired a facility in Mehsana for this and expects commercial operations at the plant to begin from March 2022, Lincoln Pharmaceuticals said in a regulatory filing.

The factory will supply all cephalosporin products such as tablets, capsules, dry syrup and injectables. The company plans to start registering its products for the domestic and export markets soon, he added.

“The entire expansion of Cephalosporin products will be funded by internal provisions. The company has earmarked a total investment of approximately Rs 30 crore for this expansion,” said Lincoln Pharmaceuticals chief executive Mahendra Patel.

The company plans to manufacture more than 20 cephalosporin products, including cefalexin BP oral suspension, clavulanate tablets, cefixime capsules, cefuroxime axetil tablets, among others, according to the filing.

It plans to export the products to markets in Africa, Latin America and Southeast Asia, he added.

“Cephalosporin is a broad-spectrum bactericidal, P-lactam antibiotic originally derived from the fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infections, angina strep throat, staph infections, tonsillitis, bronchitis and the like, “the record says.

Lincoln Pharma shares were trading at Rs 386.80 per certificate on BSE, up 1.10% from its previous close.


Source link

]]>
https://scubadivetalks.com/lincoln-pharma-allocates-approximately-rs-30-cr-for-expansion-of-cephalosporin-product-portfolio-health-news-et-healthworld/feed/ 0
Biogen and Samsung Obtain FDA Approval for Biosimilar to Roche’s Flagship Drug https://scubadivetalks.com/biogen-and-samsung-obtain-fda-approval-for-biosimilar-to-roches-flagship-drug/ https://scubadivetalks.com/biogen-and-samsung-obtain-fda-approval-for-biosimilar-to-roches-flagship-drug/#respond Mon, 20 Sep 2021 20:27:58 +0000 https://scubadivetalks.com/biogen-and-samsung-obtain-fda-approval-for-biosimilar-to-roches-flagship-drug/ Roche Lucentis’ flagship drug, a treatment for several eye disorders leading to vision loss, now has its first FDA approved biologically similar competitor, a product developed by a joint venture Biogen and Samsung BioLogics. The regulatory decision means that the newly approved drug, named Byooviz, could soon be used as a cheaper alternative to Lucentis […]]]>

Roche Lucentis’ flagship drug, a treatment for several eye disorders leading to vision loss, now has its first FDA approved biologically similar competitor, a product developed by a joint venture Biogen and Samsung BioLogics.

The regulatory decision means that the newly approved drug, named Byooviz, could soon be used as a cheaper alternative to Lucentis in the treatment of three eye disorders: the “wet” form of age-related macular degeneration (AMD); macular edema due to blockage of the veins in the retina; and myopic choroidal neovascularization, which is a complication of vision-threatening myopia.

Biologic drugs are derived from living organisms, and there is no way to make an exact copy of a cell or other biologic in the same way that a generic drug is a copy of a small one. molecule. Instead, a competing biologic drug is developed to be biologically similar or biosimilar.

Lucentis is an antibody that blocks vascular endothelial growth factor (VEGF), a signaling protein that promotes the growth of endothelial cells. This protein promotes the growth of blood vessels in the eye which are associated with several eye disorders. Roche’s drug, a chronic treatment given about once a month as an injection into the eye, generated more than 1.4 billion Swiss francs in revenue last year (about $ 1.5 billion) , an amount down 16% compared to 2019 sales. report of fourth quarter and full year financial results, the company attributed the decline in sales to the impact of Covid-19. Now the drug faces a looming competitive challenge from Byooviz.

Like Lucentis, Byooviz is also given as an ocular injection once a month. To gain FDA approval, the Biogen / Samsung Samsung Bioepis joint venture had to provide clinical data showing that its drug does not show any clinically meaningful difference in terms of safety and efficacy compared to Lucentis. U.S. regulatory approval makes Byooviz the first ophthalmic biosimilar approved in the United States, according to the FDA. The agency said it has approved 31 biosimilars to treat a variety of conditions. Byooviz’s move follows regulatory approvals for the therapy in the European Union and the UK last month.

Biogen, based in Cambridge, Mass., And Samsung BioLogics formed Samsung Bioepis in 2011, with Biogen as a minority shareholder holding approximately 5.4%. The joint venture made a small but growing contribution to Biogen sales. In 2020, Biogen reported $ 795.8 million in biosimilar revenue, an increase of over 7.7% from the previous year.

Two years ago, Biogen paid $ 700 million to Samsung BioLogics for increase your stake in the 49.9% joint venture, an agreement which also gave it exclusive rights to market Byooviz and another biosimilar candidate, SB15, in the United States, Canada, Europe, Japan and Australia. SB15 is a biosimilar that refers to Eylea, an eye medicine marketed by Regeneron Pharmaceuticals. Under an agreement between Samsung Bioepis and Genentech, a Roche subsidiary, Samsung Bioepis and Biogen could market Byooviz in the United States from June 2022, before Genentech’s patents for its drug expire. Byooviz can be marketed elsewhere after the patents expire.

Photo: Scott Eisen / Bloomberg, via Getty Images


Source link

]]>
https://scubadivetalks.com/biogen-and-samsung-obtain-fda-approval-for-biosimilar-to-roches-flagship-drug/feed/ 0
Pfizer recalls anti-smoking drug Chantix due to carcinogenic chemical https://scubadivetalks.com/pfizer-recalls-anti-smoking-drug-chantix-due-to-carcinogenic-chemical/ https://scubadivetalks.com/pfizer-recalls-anti-smoking-drug-chantix-due-to-carcinogenic-chemical/#respond Mon, 20 Sep 2021 12:59:44 +0000 https://scubadivetalks.com/pfizer-recalls-anti-smoking-drug-chantix-due-to-carcinogenic-chemical/ The voluntary recall was motivated by the presence of high levels of nitrosamine, which may increase the risk of cancer. Separately, a study showed that a drug Mirati Therapeutics that blocks the cancer protein KRAS shrunk tumors in 22% of patients with advanced colon cancer. USA Today: Chantix recall: Pfizer recalls smoking cessation drug for […]]]>

We want to hear from you: Contact us


Source link

]]>
https://scubadivetalks.com/pfizer-recalls-anti-smoking-drug-chantix-due-to-carcinogenic-chemical/feed/ 0
Three people arrested for selling banned and counterfeit drugs in Dhaka https://scubadivetalks.com/three-people-arrested-for-selling-banned-and-counterfeit-drugs-in-dhaka/ https://scubadivetalks.com/three-people-arrested-for-selling-banned-and-counterfeit-drugs-in-dhaka/#respond Sun, 19 Sep 2021 08:02:32 +0000 https://scubadivetalks.com/three-people-arrested-for-selling-banned-and-counterfeit-drugs-in-dhaka/ Those arrested have been identified as Faisal Ahmed, Sumon Chandra Mollik and Md Liton Gazi. The three men were arrested on Saturday following joint operations by detectives from the Lalbagh Division of the DMP and the Directorate-General for Drug Administration at pharmacies in the Mitford area of ​​Dhaka. Among the pharmaceuticals recovered in the raid […]]]>

Those arrested have been identified as Faisal Ahmed, Sumon Chandra Mollik and Md Liton Gazi.

The three men were arrested on Saturday following joint operations by detectives from the Lalbagh Division of the DMP and the Directorate-General for Drug Administration at pharmacies in the Mitford area of ​​Dhaka.

Among the pharmaceuticals recovered in the raid were i-pill, Super Gold Kosturi, Naproxen Plus, Betnovate C, Protobit, Eno Sanagro, Periactin Moov, Ring Guard, Wheatfield, Nix Rubbing Balm, Vicks Cold Plus, Vicks and Gacozema.

“We raided the Mitford area with the help of the drug administration branch after learning that some unscrupulous traders were selling banned and counterfeit drugs and ointments, some under local brand names and famous and lifesaving foreigners, ”said Mahbub. Alam, co-commissioner of the DMP Detective Branch (South), said at a press conference on Sunday.

The team raided Medicine World and the Aloknath Drug House on the ground floor of Sureswari Medicine Plaza and the Rafsan Pharmacy on the ground floor of Hajji Rani Medicine Market.

“As the capital’s Mitford Market is a wholesale market for pharmaceuticals, a counterfeit drug production and marketing network is using it as a stash to spread fake drugs across the country,” Alam said.

Initial questioning revealed that traders had bought these drugs and balms for sale at Mitford Market in the hope of making a profit, he said.

A complaint against those arrested was lodged with the Kotowali Police Station under the Special Powers Act.


Source link

]]>
https://scubadivetalks.com/three-people-arrested-for-selling-banned-and-counterfeit-drugs-in-dhaka/feed/ 0
Drug Shows Breakthrough Results To Extend Life Of Hard-To-Treat Breast Cancer https://scubadivetalks.com/drug-shows-breakthrough-results-to-extend-life-of-hard-to-treat-breast-cancer/ https://scubadivetalks.com/drug-shows-breakthrough-results-to-extend-life-of-hard-to-treat-breast-cancer/#respond Sat, 18 Sep 2021 16:30:00 +0000 https://scubadivetalks.com/drug-shows-breakthrough-results-to-extend-life-of-hard-to-treat-breast-cancer/ New data released on Saturday at the 2021 European Society for Medical Oncology conference is sparking excitement among those looking to tackle some of the most difficult forms of breast cancer. The researchers found that the use of the antibody conjugate drug ENHERTU to treat the currently incurable HER-2-positive breast cancer was significantly more effective […]]]>

New data released on Saturday at the 2021 European Society for Medical Oncology conference is sparking excitement among those looking to tackle some of the most difficult forms of breast cancer.

The researchers found that the use of the antibody conjugate drug ENHERTU to treat the currently incurable HER-2-positive breast cancer was significantly more effective in shrinking the tumor size and keeping the patient alive longer without progression. disease than the current TDM1 standard of care.

ENHERTU was found to be twice as effective as TDM1, the standard drug, in completely controlling disease in this trial. Both drugs are given intravenously and both are antibody-drug conjugate drugs, but ENHERTU is designed differently, which probably explains the improved results in some people.

“I am really excited about the ENHERTU data, which shows better survival rate than TDM1,” said Dr Jame Abraham, chairman of the department of hematology and oncology at the Cleveland Clinic and who was not involved in this study. “The side effects are minimal, if not zero for the majority of patients. TDM1 is a good adjuvant medicine, but we always strive to do better. ENHERTU offers this best option. “

“The result of this trial is very clinically meaningful for patients with HER-2 positive breast cancer,” Dr. Sara Tolaney, head of the breast oncology division, Dana-Farber Cancer, told ABC News. Institute, which was part of the research team. . She predicted that “this powerful antibody … will radically change the treatment of HER-2 positive breast cancer.”

Breast cancer is the world’s deadliest cancer for women, and about 1 in 5 people with breast cancer test positive for the HER-2 gene. The presence of the HER-2 protein makes breast cancer more aggressive than other types. About 1 in 3 women diagnosed with early breast cancer will see the cancer spread to other organs, and about 72% of these patients will die within five years.

ENHERTU was approved by the Food and Drug Administration in 2019 for inoperable or metastatic (spreading to other organs) HER-2-positive breast cancer. Its use was approved if the patient did not respond to standard treatment and at least two combined options were tried.

“To use ENHERTU as a prior line of treatment, the FDA required a direct controlled trial,” Dr. Sunil Verma, vice president and global clinical head of breast cancer research at AstraZeneca, told ABC News. The group therefore launched a trial in 2017, the results of which were announced publicly on Saturday.

This culminated in the Phase 3 trial, which included around 500 patients over the age of 18 in 15 countries in Asia, Europe, North America, Oceania and South America. Half were treated with ENHERTU, half with TDM1. This trial led by AstraZeneca and Daiichi Sankyo is the first global, randomized, face-to-face clinical trial for HER-2-positive breast cancer.

The trial compared the progression-free survival, or PFS, of ENHERTU to that of TDM1. PFS indicates disease control (tumor size) and looks at how long a patient lives without cancer growing or spreading. After 12 months, less than 25% of patients treated with ENHERTU experienced disease progression or death, while 65% of patients treated with TDM1 experienced disease progression or death.

The safety profile of ENHERTU was consistent with that of previous trials and no new safety issues were identified.

Verma said about 80% of patients on ENHERTU saw their tumor shrink and 16% of patients’ tumors could no longer be seen using imaging technology.

“With the remarkable results of this study, ENHERTU could become the new gold standard treatment for patients with HER-2 positive metastatic breast cancer after standard chemotherapy,” added Verma.

This promising new treatment is called second-line treatment because it is intended to be used only for progression from standard first-line treatment with chemotherapy and Herceptin. But the results suggest that it could perhaps be used earlier in place of chemotherapy.

AstraZeneca and Daiichi Sankyo are already researching whether patients with other cancers – including stomach and lung cancer – could see equally promising results with ENHERTU, Verma said, adding: on other cancers HER- 2-positive. “

Editor’s Note: This article has been updated to make it clear that the reported data results are for ENHERTU alone and not as a combination.

Dr. Madhu Vennikandam, MD, board certified internal medicine physician and gastroenterology researcher at Michigan State University with Sparrow Hospital, East Lansing, contributes to ABC News’ medical unit.


Source link

]]>
https://scubadivetalks.com/drug-shows-breakthrough-results-to-extend-life-of-hard-to-treat-breast-cancer/feed/ 0
Yale Cancer Center study shows new drug combinations improve outcomes for patients with advanced lung cancer https://scubadivetalks.com/yale-cancer-center-study-shows-new-drug-combinations-improve-outcomes-for-patients-with-advanced-lung-cancer/ https://scubadivetalks.com/yale-cancer-center-study-shows-new-drug-combinations-improve-outcomes-for-patients-with-advanced-lung-cancer/#respond Fri, 17 Sep 2021 17:58:40 +0000 https://scubadivetalks.com/yale-cancer-center-study-shows-new-drug-combinations-improve-outcomes-for-patients-with-advanced-lung-cancer/ New findings from a large study by Yale Cancer Center researchers show that adding the drugs oleclumab or monalizumab to durvalumab improved progression-free survival in patients with non-small cell lung cancer (NSCLC) locally advanced. The data is part of the COAST trial and will be presented on September 17, 2021 at the annual meeting of […]]]>

New findings from a large study by Yale Cancer Center researchers show that adding the drugs oleclumab or monalizumab to durvalumab improved progression-free survival in patients with non-small cell lung cancer (NSCLC) locally advanced. The data is part of the COAST trial and will be presented on September 17, 2021 at the annual meeting of the European Society for Medical Oncology (ESMO).

“Our results from the COAST trial are very encouraging as the data suggests that these novel combinations of immunotherapy drugs may improve clinical outcomes for patients with advanced NSCLC,” said Roy S. Herbst, MD, Ph.D., chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital and lead author of the study. “The majority of patients with NSCLC are diagnosed with tumors that cannot be removed by surgery, but advances in chemotherapy and radiation therapy have been shown to be effective. We are using our scientific laboratory research to provide new and more effective therapies after radiation therapy to improve survival. ”

COAST is a phase 2, randomized, open-label trial that investigated adjuvant treatment with durvalumab alone or in combination with oleclumab or monalizumab in patients with locally advanced, unresectable stage III NSCLC. Durvalumab works with a patient’s immune system to interfere with the growth and spread of cancer cells in the body. The results show that oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with durvalumab improved progression-free survival. After a follow-up of 11.5 months, data showed that durvalumab in combination with oleclumab reduced the risk of disease progression or death by 56%, and in combination with monalizumab by 35%, compared with durvalumab alone. The 10-month progression-free survival rate was 64.8% for durvalumab plus oleclumab and 72.7% for durvalumab plus monalizumab, compared with 39.2% for durvalumab alone.

“These results support further evaluation of these drug combinations and have helped us better understand the important challenges of immunotherapy sensitivity and resistance,” Herbst said. “This year, it is estimated that more than two million people around the world are diagnosed with lung cancer; our work continues on behalf of these patients.

This study was funded by AstraZeneca.

Submitted by Anne Doerr on September 16, 2021


Source link

]]>
https://scubadivetalks.com/yale-cancer-center-study-shows-new-drug-combinations-improve-outcomes-for-patients-with-advanced-lung-cancer/feed/ 0
Long-term injectables and counseling improve treatment adherence in patients with bipolar disorder https://scubadivetalks.com/long-term-injectables-and-counseling-improve-treatment-adherence-in-patients-with-bipolar-disorder/ https://scubadivetalks.com/long-term-injectables-and-counseling-improve-treatment-adherence-in-patients-with-bipolar-disorder/#respond Fri, 17 Sep 2021 05:09:00 +0000 https://scubadivetalks.com/long-term-injectables-and-counseling-improve-treatment-adherence-in-patients-with-bipolar-disorder/ Researchers found that medication adherence improved in people with bipolar disorder through the use of long-term injectable medications combined with psychosocial intervention. Research results from the University Hospitals (UH) Cleveland Medical Center and the Case Western Reserve University (CWRU) School of Medicine appear in the September 16, 2021 issue of The journal The Primary care […]]]>

Researchers found that medication adherence improved in people with bipolar disorder through the use of long-term injectable medications combined with psychosocial intervention.

Research results from the University Hospitals (UH) Cleveland Medical Center and the Case Western Reserve University (CWRU) School of Medicine appear in the September 16, 2021 issue of The journal The Primary care companion for CNS disorders.

Poor adherence to treatment is widespread in people with bipolar disorder and is often associated with negative results. A growing body of literature focuses on clinical approaches to remedy poor adhesion that can lead to substantial improvements in outcomes for this group of people. “

Martha Sajatovic MD, Principal Study Author and Director, Center for Neurological and Behavioral Outcomes, CWRU School of Medicine

Martha Sajatovic is also director of UH Cleveland Medical Center.

Bipolar disorder is a mental health problem that causes extreme mood swings that include emotional highs (mania or hypomania) and lows (depression).

The study recruited 30 people with bipolar disorder who had problems with adhesion. More than 20 percent of them said they missed their bipolar medication in the previous week or month at the initial screening.

For the study, participants were given the long-acting injectable (LAI) antipsychotic drug aripiprazole, approved by the U.S. Food and Drug Administration (FDA) for the treatment of bipolar disorder.

“However, despite the adhesion benefits of long-acting injectable drugs, just using them may not be enough to maintain long-term behavior change,” said Dr Sajatovic. “Our pilot trial combined LAI with a brief behavioral approach called personalized adhesion improvement (CAE). Together we called them CAE-L to assess the effects on adhesion, symptoms of bipolar disorder and functional condition, ”she said.

The CAE was delivered by a trained social worker following a detailed schedule and delivered at the same clinic visit when patients came to collect their medications. Barriers to adherence, Dr Sajatovic said, could be made up of several things, including a lack of drug education; communication problems with suppliers; strategies for improving medication routines and substance abuse problems.

CAE is a brief and practical intervention program designed to tackle an individual’s specific barriers to membership. Each module could be combined with other modules as determined by a prior assessment. For this study, the EAC was performed in seven sessions (an initial baseline session, followed by one session each month for the six months of the study).

The drug was also administered once a month for six months. Participants also continued other maintenance treatments such as mood stabilizing drugs (lithium, valproate, or lamotrigine) or prescribed antidepressants and hypnotics for at least one month prior to enrollment.

“Overall, our results suggest that a personalized intervention to overcome barriers to adherence combined with IAT can dramatically improve outcomes in high-risk people with bipolar disorder,” said Dr. Sajatovic.

By the end of six months, self-reported adherence behaviors improved. Adhesion remained stable and bipolar symptoms improved.

CAE-L was associated with excellent adherence to LAI (100% of people received the injection within a week of scheduled time), compared to initial screening where people missed an average of 50.1% of medications orals prescribed during the previous week and 40.6% of drugs during the last month.

The proportion of medications missed in the week between screening and 24 weeks improved significantly from 50.1% to 16.9%, and last month from 40.6% to 19.2 %.

From baseline to week 24, there were significant decreases in bipolar disorder symptoms and overall psychopathology. Function improved significantly between baseline and week 24. Participants also found the CAE intervention to be highly acceptable.

Limitations of the study include the small sample size, the lack of a control group for comparison, and all patients from one hospital site. An additional limitation is that adherence was based on self-report, which has the potential to underestimate missed medications. Twenty-one completed the trial out of the initial 30 that began (nine participants dropped out of the study prematurely for various reasons).

Source:

Journal reference:

Sajatovic, M., et al. (2021) Long-acting injectable antipsychotic drugs and personalized adherence improvement in patients with low adherence with bipolar disorder. Primary care companion for CNS disorders. doi.org/10.4088/PCC.20m02888.


Source link

]]>
https://scubadivetalks.com/long-term-injectables-and-counseling-improve-treatment-adherence-in-patients-with-bipolar-disorder/feed/ 0
Veterinarian professor warns of ivermectin as COVID drug https://scubadivetalks.com/veterinarian-professor-warns-of-ivermectin-as-covid-drug/ https://scubadivetalks.com/veterinarian-professor-warns-of-ivermectin-as-covid-drug/#respond Thu, 16 Sep 2021 19:13:36 +0000 https://scubadivetalks.com/veterinarian-professor-warns-of-ivermectin-as-covid-drug/ Western College of Veterinary Medicine Associate Dean Says Risk of Overdose Is High When Using Livestock Medication Animal doses of ivermectin should not be used to treat or ward off COVID-19, says Chris Clark, professor of animal science at the University of Saskatchewan. Clark, who is also associate dean of the Western College of Veterinary […]]]>

Western College of Veterinary Medicine Associate Dean Says Risk of Overdose Is High When Using Livestock Medication

Animal doses of ivermectin should not be used to treat or ward off COVID-19, says Chris Clark, professor of animal science at the University of Saskatchewan.

Clark, who is also associate dean of the Western College of Veterinary Medicine, said the advice is supported by a recent review of the literature by the Cochrane Library, a group of doctors around the world who are reviewing multiple publications and trying to find consensus. .

“They could only find 14 studies that were of value,” he said.

The review concluded: “Based on the current very low to low certainty evidence, we are uncertain about the efficacy and safety of ivermectin used to treat or prevent COVID-19. The completed studies are small and few are considered to be of high quality… Overall, the available reliable evidence does not support the use of ivermectin for the treatment or prevention of COVID-19 outside of trials well-designed randomized.

A published study has been withdrawn.

Neither Health Canada nor the United States Food and Drug Administration has approved the use of ivermectin for the treatment or prevention of COVID.

The FDA recently tweeted, “You are not a horse. You are not a cow. Seriously all of you. Stop that.”

Clark said ivermectin is used in cattle to treat intestinal roundworms and parasites.

In humans, it is used to treat parasites and certain skin conditions.

At the start of the pandemic, some trials were using it as a COVID treatment. Clark describes them as “very bad ordeals.”

People who take the animal version of the medicine do so at great risk. The risk of overdose is extremely high since the doses have been developed for animals weighing 500 kilograms or more.

Even among species, the formulations differ. There are equine and bovine types. And for cattle, there are oral, injectable and pour-over formulations.

“I have a doctorate in pharmacology and I will never consider using a product for one species over another. Even with all of my knowledge, I can’t predict what’s going to happen, ”Clark said.

He said he understands people are frustrated with COVID and want a solution, but that’s not it.

The Cochrane Library review noted that 31 studies are ongoing and more information may come to light.

For now, Clark has said people should listen to their doctors and read labels. Veterinary drugs will say no for human use and do not say ivermectin can be used for corona viruses.

“You have to read the label and trust it more than what you see on Facebook or Twitter,” he said.


Source link

]]>
https://scubadivetalks.com/veterinarian-professor-warns-of-ivermectin-as-covid-drug/feed/ 0
HHS ‘plan to cut prescription drug costs is a good start, but we need bold and swift action https://scubadivetalks.com/hhs-plan-to-cut-prescription-drug-costs-is-a-good-start-but-we-need-bold-and-swift-action/ https://scubadivetalks.com/hhs-plan-to-cut-prescription-drug-costs-is-a-good-start-but-we-need-bold-and-swift-action/#respond Tue, 14 Sep 2021 18:30:31 +0000 https://scubadivetalks.com/hhs-plan-to-cut-prescription-drug-costs-is-a-good-start-but-we-need-bold-and-swift-action/ September 14, 2021 7 minutes to read Source / Disclosures Disclosures: Kuwahara reports serving on the National Steering Committee for Prescription Drug Affordability at Doctors for America. ADD A SUBJECT TO E-MAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are […]]]>

September 14, 2021

7 minutes to read

Disclosures: Kuwahara reports serving on the National Steering Committee for Prescription Drug Affordability at Doctors for America.


We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact customerservice@slakinc.com.

HHS recently announced a plan support legislation that would allow it to negotiate the prices of Medicare Part B and Part D drugs directly with drug companies, and then make those prices available to other buyers, in addition to other key policy proposals to reduce drug costs. medications.

In this guest editorial, Rita K. Kuwahara, MD, MIH, a primary health care policy researcher and internal medicine physician at Georgetown University, discusses the HHS plan and explains how affordable drugs would allow providers to focus on responsive care to preventive medicine, which in turn would improve health outcomes and lower overall health care costs.

As a primary care physician, I have seen firsthand how access to affordable medicines can mean the difference between life and death for my patients.

For my diabetic patients who need insulin to survive, it is unacceptable that their ability to live or die depends on the type of drug coverage they have and whether they can afford the sky-high cost of it. insulin.

We are at a critical time when our nation has the capacity to make medicines affordable for all, but it is essential that we put health before politics and show that as a nation we aim to ensure that everyone can. access the medicines they need when they need them.

The Biden-Harris administration is to be applauded for its leadership and commitment to lowering prescription drug prices. This is an important first step, but much more can and must be done, and the administration has the power to do it.

Every person in our country needs access to affordable medicine now, and we cannot afford to wait. We are currently in the midst of a pandemic, which has made essential medicines financially inaccessible to many people who have lost their jobs and employer-sponsored health insurance, and inaction will cost lives.

Pharmaceutical companies have for too long taken advantage of people’s poor health and benefited from generous policies that allow their profits to grow unchecked. For example, pharmaceutical companies set the prices of drugs; Unlike other high-income countries, the United States does not negotiate these prices, resulting in prescription drug costs 2.5 times higher than those of other high-income countries, according to a report by the RAND Corporation. What’s more, even during the pandemic, a recent AARP report found that “between 2019 and 2020, the retail prices of 260 widely used brand-name prescription drugs increased 2.9%, more than two times faster than general inflation “.

While I hope Congress is able to come together and pass comprehensive legislation to make drugs affordable for everyone in our country, it is essential that the administration use all the powers of the executive to ensure that everyone has access to affordable products, life-saving medicines whenever they need them, because disease is never planned and health should not be a commodity, but rather a human right.

It makes sense that in a free market economy Medicare would be able to negotiate the prices of prescription drugs, and since drug companies already benefit from public funds that support initial drug development, mechanisms should be in place to limit additional patient expenses – out-of-pocket costs for prescription drugs.

In the current model, it is important to note that patients often end up paying two to three times for their medication. They pay first through their taxes which support NIH funding, since the 356 drugs that were approved by the FDA between 2010 and 2019 were supported by NIH funding. Our patients are paying a second time through their health insurance premiums, which continue to rise with the rising cost of health care in the United States. They are then billed a third time when they collect their medication from the pharmacy.

The unreimbursed drug costs that families pay at the pharmacy counter have also increased, as co-payments increasingly depend on drug pricing, rising health insurance deductibles, and the increasing shift in drug use. co-payments to the percentage of coinsurance owed by patients to purchase their prescription drugs.

Since access to affordable medicines is essential for maintaining good health, we need bold and decisive action now to lower the cost of prescription drugs and make drugs affordable for everyone so that each of our patients and everyone in our community can access the medicines they need.

As a member of the National Steering Committee for Prescription Drug Affordability at Doctors for America, my colleagues and I have continued to advocate for strategies to reduce drug costs for our patients through executive action and legislative.

During HHS Secretary that of Xavier Becerra confirmation process earlier this year, Doctors for America sent key questions about drug affordability to the Senate Finance Committee to ask Becerra, highlighting some of the issues the administration has the power to act on. This included advocating for the use of “the federal authority to demand treatments and vaccines for COVID-19 to ensure affordable access for all”, the commitment “to all mechanisms available (e.g. market rights, Section 1498, Defense Production Act) to ensure that Americans don’t continue to receive a bad deal from drug companies that deny access to treatments and vaccines lifesavers of which they are true investors, “ensuring that” the NIH and the FDA apply sanctions for failure and delay in reporting clinical trial results, “supporting” efforts to ensure that Medicare and other insurers can negotiate directly with pharmaceutical companies to reduce the cost of all prescription drugs “, and” offering a total of 5 years of exclusivity for all biologic drugs s instead of the current 12 years that have led to exorbitant monopoly prices for these treatments.

These concrete proposals, some of which have already been adopted by the administration, represent examples of policies that can be used to create a framework of action that the administration can take to reduce prescription drug costs for everyone in our region. country.

It is not fair that our current system prioritizes profits over health, which leaves us with patients every day who cannot afford their drugs. We urgently need access to affordable medicines for all to improve the health of our nation.

This is even more evident during the COVID-19 pandemic, with many families no longer able to afford necessary medications due to financial exhaustion and loss or change in insurance coverage. At the same time, however, the COVID-19 pandemic has given us insight into how we can improve public health and the health of our communities if we make health care accessible and affordable for all.

For the first time as a practicing physician in the United States, when patients come to me and need to be vaccinated against COVID-19, I can now tell them that they can get the vaccine regardless of the type of insurance. , their ability to pay and how much money is in their bank account simply because as taxpayers they have already paid for the development, purchase and distribution of COVID-19 vaccines, and the vaccines, purchased by the government with taxpayer money, are now available without sharing additional costs for the sick. This has been essential, especially as we are trying to increase immunization rates to keep everyone safe. If only we had the same luxury of being able, for example, to ensure that diabetic patients have access to insulin, we wouldn’t have people with diabetes who die or develop serious complications because they have to ration or forgo completely. take their insulin because of the cost.

Regarding COVID-19 vaccines, given that the government and taxpayers have already invested significant funds in the development and distribution of vaccines, the government should have the capacity to negotiate the price of vaccines because of large-scale vaccination campaigns. are organized across the country. in an effort to curb the current pandemic, rather than having to pay increasingly higher prices for vaccines as manufacturers arbitrarily raise prices, which will ultimately increase health spending and costs to taxpayers.

It is essential that we as a nation make medicines affordable for all, so that we can practice preventive medicine rather than reactive care and in doing so reduce overall health care costs with a focus on improving health outcomes so that everyone is healthy enough to live, work and care for their families.

As physicians, we need to give our patients a voice and use our power to communicate the experiences of our patients who cannot afford essential medicines to advocate for pricing policy reform. prescription drugs.

The references:

Editor’s Note: This interview reflects the views and opinions of Kuwahara and not its affiliations or institutions.


Source link

]]>
https://scubadivetalks.com/hhs-plan-to-cut-prescription-drug-costs-is-a-good-start-but-we-need-bold-and-swift-action/feed/ 0